MedWatch

Novo’s Tresiba beats Sanofi’s Lantus in Devote trial

Novo Nordisk has revealed headline results from its major CV trial Devote, showing that its long-acting inuslinTresiba was superior to Sanofi’s blockbuster Lantus in reducing the risk of dangerously low blood sugar in diabetes patients.

Foto: Novo Nordisk

Novo Nordisk’s ultra-long-acting basal insulin Tresiba (insulin degludec) has been shown to be superior to French rival Sanofi’s Lantus (insulin glargine) in reducing severe cases of low blood sugar. This is according to a press release from the Danish diabetes group.

Novo has released the headline results from its major cardiovascular risk trial Devote, which the US FDA asked it to conduct after the agency initially rejected approval of Tresiba back in 2013.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier